5th February 2020
12th April 2013
20th May 2012
Medicine Compliance Aid Stability
Betmiga · Astellas Pharma Ltd
Astellas Pharma Ltd
Tablets m/r 25mg, 50mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Protect from moisture in an airtight container.
21st September 2015
Lactation Safety Information
Long half-life increases risk of accumulation in breastfed infants
No published evidence of safety
Betmiga (EU) Myrbetriq (US) · Neurogenic detrusor overactivity in children
Betmiga (EU) Myrbetriq (US)
Licence extension / variation
Development and Regulatory status
Phase III Clinical Trials
Beta 3 receptor agonist
The incidence of the problem is reported as 8.4% in girls and 1.7% in boys .
Neurogenic detrusor overactivity in children